Cigna's Evernorth Health Services said on Wednesday its actions will enhance transparency about the company's negotiations.

FTC stated that the 'Big 3' PBM organisations collectively generated over £5.94 billion ($7.3 billion) in revenue from 2017 to 2022.

The lawsuit claims that three major healthcare companies were pushing up the price of insulin by 1,200 percent.

Discover how the three largest pharmacy benefit managers are rejecting biosimilars from their formularies, except for their own private-label drugs.

Pharmacy benefit managers CVS Caremark, OptumRx and Express Scripts inflated costs ... The CVS Health subsidiary, UnitedHealth Group division and Cigna subsidiary employed tactics such as marking ...

The City of Greensboro, North Carolina, which provides public safety, emergency, and health services to over 300,000 residents and spends millions annually on insulin medications, filed a lawsuit last ...

We recently published a list of 10 Companies Reflect Market Decline. In this article, we are going to take a look at where UnitedHealth Group Incorporated (NYSE:UNH) stands against other companies ...

UnitedHealth Group Incorporated (NYSE ... According to the report, UnitedHealth’s OptumRx, along with Cigna’s Express Scripts and CVS Caremark Rx, were able to collectively pocket $7.3 billion ...

Investing.com -- Shares of CVS Health Corp (NYSE:CVS), Cigna (NYSE:CI) Group, and UnitedHealth ... Cigna’s Express Scripts, and UnitedHealth’s OptumRx — imposed markups of hundreds to ...

On Tuesday, the U.S. Federal Trade Commission (FTC) presented evidence that UnitedHealth Group’s OptumRx, along with its two main competitors, Express Scripts and CVS Caremark Rx, inflated the ...